Psoriasis treatment: Traditional therapy

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 2, 2005, Pages

  Lebwohl, M ^a,c   Ting, P T ^b   Koo, J Y M ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMCINONIDE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DESOCORT; DESONIDE; DESOXIMETASONE; DEXAMETHASONE; DIFLORASONE DIACETATE; ETRETIN; ETRETINATE; FLUDROXYCORTIDE; FLUOCINONIDE; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE VALERATE; HYDROXYUREA; METHOTREXATE; MOMETASONE FUROATE; RETINOID; TACALCITOL; TACROLIMUS; TAZAROTENE; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ACNE; APHTHOUS STOMATITIS; BONE MARROW TOXICITY; CALCIFICATION; CHEILITIS; CLIMATOTHERAPY; CONFERENCE PAPER; DEATH; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; LIVER DYSFUNCTION; LIVER FIBROSIS; LYMPHOPROLIFERATIVE DISEASE; MEGALOBLASTIC ANEMIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PARONYCHIA; PERIORAL DERMATITIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; PYOGENIC GRANULOMA; SIDE EFFECT; SKIN ATROPHY; SKIN IRRITATION; SKIN TOXICITY; STRIA; SYSTEMIC THERAPY; TACHYPHYLAXIS; TELANGIECTASIA; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADRENAL CORTEX HORMONES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOTHERAPY; PSORIASIS;

EID: 14244260387     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.030791     Document Type: Conference Paper

References (33)

1. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-98.
2. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-61.
3. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-7.
4. Feldman SR, Sangha N, Setaluri V. Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. J Am Acad Dermatol 2000;42:1017-20.
5. Andreassi L, Giannetti A, Milani M. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, uncontrolled, cross-over study on 241 patients. Br J Dermatol 2003;148:134-8.
6. Pierard GE, Pierard-Franchimont C, Ben Mosbah T, Arrese Estrada J. Adverse effects of topical corticosteroids. Acta Derm Venereol Suppl (Stockh) 1989;151:26-30; discussion 47-52.
7. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review. Drugs 1988;36(suppl):551-61.
8. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic- pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000;105(4 Pt 1):794-9.
9. Scott LJ, Dunn O, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2001;2:95-120.
10. Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38:1010-1.
11. Lebwohl M, Quijije J, Gilliard J, Rollin T, Watts O. Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol 2003;121:594-5.
12. Koidbey K, Kopper SC, Sefton J, Gibson JR. A pilot study to determine the effect or tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol 2001;40:468-71.
13. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.
14. Perry HO, Soderstrom CW, Schulze RW. The Goeckerman treatment for psoriasis. Arch Dermatol 1968;98:178-82.
15. Pittelkow MR, Perry HO, Muller SA, Mauqhan WZ, O'Brien PC. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol 1981;117:465-8.
16. Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 1997;133:1514-22.
17. Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol 1999;140:887-90.
18. Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 2002;47:701-8.
19. Coven TR, Walters IB, Cardinale I, Krueger JG. PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed 1999;15:22-7.
20. Gorham H. Treatment of psoriatic arthropathy by PUVA. Physiotherapy 1980;66:40.
21. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998;90:1278-84.
22. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997;336:1041-5.
23. Abels DJ, Rose T, Bearman JE. Treatment of psoriasis at a Dead Sea dermatology clinic. Int J Dermatol 1995;34:134-7.
24. Schiffner R, Schiffner-Rohe J, Wolfl G, Landthaler M, Glassl A, Walther T, et al. Evaluation of a multicentre study of synchronous application of narrowband ultraviolet B phototherapy (TL-01) and bathing in Dead Sea salt solution for psoriasis vulgaris. Br J Dermatol 2000;142:740-7.
25. Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:72-6.
26. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995;34(suppl):220-5.
27. Haagsma CJ. Clinically important drug interactions with disease-modifying antirheumatic drugs. Drugs Aging 1998;13:281-9.
28. van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on tfie toxicity and efficacy of melhotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
29. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85.
30. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993;100:623-7.
31. Lebwohl M, Drake L, Menter A, Koo J, Gottlieb AB, Zanolli M, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001;45:544-53.
32. Klinkhoff AV, Gertner E, Chalmers A, Gladman DD, Stewart WD, Schachter GD, et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989;16:789-91.
33. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464-75.